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INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most 
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Objective: To evaluate the effectiveness of ultrasound-guided radiofrequency (RF) ablation in patients with incompletely 
treated hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) and to evaluate possible 
prognostic factors for this therapy. 
Subjects and Methods: Thirty nine patients with incompletely treated single HCC (≤ 5 cm) after TACE were treated with RF 
ablation. All patients were evaluated for complete tumor ablation rate, local recurrence-free rate, overall survival rate, and 
complications. Local recurrence-free rate and overall survival rate were calculated using the Kaplan-Meier method. The 
possible prognostic factors of local recurrence-free rate and survival rate were analyzed using Cox proportional-hazards 
regression model.
Results: The complete tumor ablation rate was 92.3%. Local recurrence-free rates for 1-, 2-, 3-, and 5-years were 81.7%, 
63.1%, 53.6%, and 35.7%, respectively. One-, 2-, 3-, and 5-year overall survival rates were 96.9%, 82.9%, 67.8%, and 
48.4%, respectively. Among prognostic factors included in the analysis, only tumor diameter (≤ 2 cm versus > 2 cm) was 
statistically significant in terms of predicting local recurrence. Complications were observed in two patients, one with liver 
abscess and the other with portal venous thrombosis.
Conclusion: Ultrasound-guided RF ablation could be effective and safe in treating incompletely treated HCC after TACE. The 
diameter of HCC was a significant prognostic factor for local recurrence.
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prevalent malignancies worldwide (1). Monitoring patients 
at high risk for HCC with imaging studies and blood tests 
for alpha-fetoprotein levels leads to diagnosis of many 
cases when there are only one or a few lesions, and the 
patient is still asymptomatic (2). Furthermore, several non-
surgical modalities have been developed for the treatment 
of unresectable HCC even with a single HCC, including 
cryoablation or radiofrequency (RF) ablation, percutaneous 
ethanol injection (PEI), and transcatheter arterial 
chemoembolization (TACE). Of those, RF ablation is one 
of the most widely performed procedures for patients with 
unresectable HCC because of its effectiveness and safety 
in the treatment of small (≤ 3 cm) and medium (≤ 5 cm) 
HCC, with a 3-year survival rate of 62-68%, a treatment-
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associated morbidity rate of 0-12%, and a treatment-related 
mortality rate of 0-1% (3-8).
RF ablation has recently gained attention as a more 
promising technique for the treatment of HCC (8-16). Many 
investigators have reported that RF ablation for patients 
with HCC provides favorable survival rates with excellent 
local recurrence-free rates (17).  
Meanwhile, TACE has been widely used in cases of 
unresectable HCC during the past 20 years. But, some 
authors report that complete tumor necrosis after TACE 
is unusual (18), thus alternative treatment is considered. 
Even when initial remission is demonstrated after TACE, 
local recurred HCC is frequently observed, and subsequently 
repeated TACE is considered. To our knowledge, there are 
few studies evaluating the rate and prognostic factors for 
local recurrence and survival after RF ablation in patients 
with incompletely treated HCC who had undergone TACE. 
The purpose of this study was to retrospectively evaluate 
the effect of ultrasound-guided RF ablation in patients with 
incompletely treated HCC after TACE. In addition, possible 
prognostic factors regarding the efficacy of this therapy 
were also evaluated.
SUBJECTS AND METHODS
Patients
Between June 2002 and September 2007, 116 consecutive 
patients with incompletely treated HCCs after TACE were 
referred to the department of radiology for RF ablation. 
Inclusion criteria for this study were as follows: 1) a single 
HCC smaller than or equal to 5 cm in diameter; 2) lesions 
visible on ultrasonography (US), with an acceptable and 
safe path between the lesion and the skin as observed on 
the US scan; 3) no extrahepatic metastases present; 4) no 
imaging evidence of tumor invasion into the major portal 
or hepatic vein branches; 5) liver cirrhosis classified as 
Child-Pugh class A or B; 6) no history of encephalopathy, 
ascites refractory to diuretics, or variceal bleeding, and 7) 
no previous treatment for HCC except TACE. Consequently, 
39 patients with a single HCC (33 men and 6 women; age 
range 48-84 years; mean age 66 years) were enrolled in this 
study. Tumor size ranged from 1.1 to 5.0 cm in diameter 
(mean, 2.4 cm).
The diagnosis of incompletely treated HCC was made 
when there were areas within HCC that had not undergone 
complete necrosis based on the follow-up CT or MR 
imaging performed within 1 month after TACE. These areas 
were considered to be present by observing incomplete 
accumulation of lipiodol within HCC or arterially enhancing 
portion within HCC on follow up CT or MR imaging (19). Of 
the 39 patients, 22 patients were treated with one cycle 
of TACE, 13 patients with 2 cycles and 4 patients with 3 
cycles. 
 
Radiofrequency Ablation
All RF ablation was performed percutaneously under 
real-time sonographic guidance. A 20 or 15 cm long, 
17 G, Cool-tip electrode with a 2 or 3 cm long exposed 
metallic tip (Valleylab, Boulder, CO, USA) was used to 
deliver radiofrequency energy. A 200 W, 480 kHz monopolar 
radiofrequency generator (CC-1, Valleylab, Boulder, CO, USA) 
was used as the energy source. A standard grounding pad 
(Valleylab, Boulder, CO, USA) was placed on each of the 
patient’s thighs. 
RF ablation procedures were performed with the patient 
under local anesthesia in the ultrasonography suite. The 
most appropriate approach was determined to avoid 
damaging large vessels near the targeted HCC, and then a 
single electrode was directly inserted through the skin and 
positioned at the center of the HCC under US guidance using 
a 3.75 MHz convex probe. The tip of the electrode was then 
further advanced to the deepest margin of the tumor. RF 
energy was applied for 8-12 min in each treatment session. 
During the procedure, a thermocouple embedded within 
the electrode tip continuously measured the temperature 
of the tip; tissue impedance was monitored by circuitry 
incorporated within the generator. When the desired current 
could not be applied without observing an elevation in 
impedance suggestive of tissue boiling, the generator 
automatically switched to the pulsed-RF technique. At the 
end of treatment, the RF ablation application and cooling 
circuits were simultaneously interrupted, and the heated 
tissues were allowed to heat the electrode by diffusion 
until the maximum temperature was recorded. To prevent 
bleeding, bile leakage, and tumor seeding, the intrahepatic 
needle track was treated with thermocoagulation and the 
electrode was removed. Tumors larger than 3.5 cm needed 
multiple overlapping ablations (20). 
Posttreatment Assessment and Follow-up
One hour after the initial treatment, contrast-enhanced 
dynamic CT was performed. When the thickness of the 
ablative margin was at least 0.5 cm for ablation of index 
tumor, the treatment was completed. When a residual 
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enhanced lesion was seen on dynamic CT, an additional 
RF ablation was performed for the residual enhanced 
lesion. The effectiveness of the RF ablation technique was 
evaluated with dynamic CT performed 1 month after the 
first RF ablation session was performed. When no enhancing 
lesion was seen on CT, the technique effectiveness was 
defined as complete. When residual enhancing lesion was 
still seen on CT, the technique effectiveness was defined 
as incomplete. The HCCs showing incomplete technique 
effectiveness were not treated with additional RF ablation 
but rather with TACE. 
Thereafter, the patients were evaluated on scheduled 
follow-ups every 2-4 months with contrast-enhanced 
dynamic CT to detect local recurrence. Local recurrence 
was defined as the development of tumoral enhancement 
in or around the ablation zone as observed on follow-up 
CT. Additionally, overall survival was evaluated and defined 
as the interval between the first RF ablation and either 
death or last follow-up visit. At each follow-up visit, blood 
tests, including those for liver function and serum alpha-
fetoprotein levels, were performed.
Possible Prognostic Factors Influencing Local Recurrence 
and Overall Survival
Ten possible prognostic factors were postulated and each 
was divided into two categories for analyses. The possible 
prognostic factors were tumor size (≤ 2 cm or > 2 cm 
maximum dimension), number of previous TACE treatments 
(1 or ≥ 2), patient age, patient gender, antibody against 
hepatitis C virus (anti-HCV) (positive or negative), hepatitis 
B surface antigen (HBs Ag) (positive or negative), Child-
Pugh class (A or B), history of alcoholic liver disease (yes 
or no), level of alpha-fetoprotein (≤ 100 ng/mL or > 100 
ng/mL), and interval between TACE and RF ablation (≤ 2 
months or > 2 months).
A
D
B
E
C
F
Fig. 1. 3 cm HCC in 66-year-old woman with no local recurrence during long term follow-up (3 years). 
A. Axial arterial-phase CT scan obtained before RF ablation shows early enhancement (arrow) in sparsely lipiodol uptake HCC after TACE. B. Axial 
arterial-phase CT scan obtained 1 hour after RF ablation shows ablation zone (arrow) with surrounding rim of benign enhancement. C-F. Axial 
arterial-phase CT scans from 1-month (C), 1-year (D), 2-year (E) and 3-year (F) follow-ups show progressive involution of ablation zone without 
local recurrence (arrow). HCC = hepatocellular carcinoma, TACE = transcatheter arterial chemoembolization, RF = radiofrequency
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A B
Fig. 2. 3.8 cm HCC in 48-year-old man with incomplete tumoral necrosis. 
A. Axial arterial-phase CT scan obtained before RF ablation shows early enhancement (arrows) in defective lipiodol uptake HCC after TACE. B. 
Axial arterial-phase CT scan obtained 1 hour after RF ablation shows irregular perilesional enhancement (arrows). C. Axial arterial-phase CT scan 
obtained 1 month after RF ablation shows disappearance of perilesional enhancement (arrows). D. CT scan obtained at more superior level than C 
shows enhancing portion (arrowhead) at periphery of ablation zone, which was subsequently treated with TACE. HCC = hepatocellular carcinoma, 
TACE = transcatheter arterial chemoembolization, RF = radiofrequency
C D
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Statistical Analyses
The complete ablation rate and major complication rate 
were calculated. The local recurrence free rate and overall 
survival rate were evaluated using the Kaplan-Meier method. 
Possible prognostic factors influencing local recurrence 
and overall survival were analyzed using a Cox proportional 
hazards regression model. The level of significance (p 
value) was set at 0.05 for all tests. SPSS statistical analysis 
software (SPSS Inc.) was used. 
RESULTS
RF Ablation Procedures and Complications
In 36 (92.3%) of 39 patients, complete tumor ablation 
was depicted on dynamic CT performed 1 month after 
treatment (Fig. 1). The 3 patients with a single HCC showing 
an incomplete response were not treated with a second RF 
ablation treatment because of the heat sink effect from the 
adjacent portal vein in one patient and large diameter (5 
cm and 3.8 cm, respectively) in other 2 patients (Fig. 2). 
Afterward, the 3 patients in whom RF ablation treatment 
failed underwent subsequent TACE.
No procedure-related death was observed. Complications 
were observed in two (5.1%) of 39 patients. Hepatic 
abscess, which was a major complication, occurred in one 
patient. The patient had developed a high fever 7 days 
after RF ablation and the CT findings in the ablated zone 
was similar to those of a hepatic abscess. Subsequently, US-
guided percutaneous drainage was performed. Portal venous 
thrombosis was observed in the other patient which was a 
minor complication.
Local Recurrence Analysis
The follow-up periods ranged from 90 to 1950 days (mean 
767 days). The local recurrence free rates at 1, 2, 3, and 5 
years were 81.7%, 63.1%, 53.6%, and 35.7%, respectively 
(Fig. 3). During the follow-up period, local recurrence 
developed in 13 (33.3%) of 39 patients. At the time of 
local tumor recurrence, distant recurrence was observed in 
3 (7.7%) of 39 patients. Tumor diameter was found to be a 
significant prognostic factor affecting local recurrence (p = 
0.047) (Table 1).
 
Survival Analysis
The overall survival rates at 1, 2, 3, and 5 years, were 
96.9%, 82.9%, 67.8%, and 48.4%, respectively (Fig. 4). No 
significant prognostic factors affecting overall survival rate 
were found (Table 2).
DISCUSSION
TACE is a widely used therapeutic modality for 
unresectable HCC and has an excellent anti-tumor effect 
(21-23). However, the efficacy of TACE remains controversial 
(24) because HCC is sometimes resistant to TACE treatment. 
Hashimoto et al. (25) reported that TACE induced complete 
necrosis only in 50% of single nodular type tumors. 
While treatment of TACE-resistant HCC is a major clinical 
objective, RF ablation has been accepted as a safe and 
useful technique for the local treatment of HCC. In the 
present study, we found that RF ablation for incompletely 
treated HCC after TACE produced a relatively high complete 
ablation rate. Our findings are consistent with previous 
studies. Shibata et al. (26) reported that complete ablation 
was achieved in 46 (96%) of 48 HCCs (≤ 4 cm) treated with 
RF ablation. Lencioni et al. (16) reported that complete 
ablation was achieved in 63 (91%) of 69 HCCs (≤ 5 cm). 
Moreover, the side effects and the long-term impairment 
of liver function associated with TACE (27, 28) further 
supports the use of RF ablation rather than subsequent 
repeated TACE treatments.
Of the three cases we considered to result in incomplete 
ablations, two cases were relatively large tumors that were 
5 cm and 3.8 cm in diameter, respectively. It was reported 
that in HCCs less than 3 cm in diameter, complete ablation 
rate was 90%, but complete ablation rate was 71% in HCCs 
Fig. 3. Graph illustrates local recurrence free rate. 1-, 2-, 3-, 
and 5-year local recurrence free rates were 81.7%, 63.1%, 53.6%, and 
35.7%, respectively. 
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ranging 3-5 cm and 25% in HCCs over 5 cm in diameter (9, 
12, 29). In the third case, we found the HCC was located 
between large branches of hepatic vessels, so it may have 
caused incomplete ablation because blood flow promotes 
heat loss, creating a so called heat sink effect. 
Our study achieved comparable local recurrence-free rates 
and survival rates as demonstrated in previous studies of 
RF ablation alone for the treatment. Other studies have 
reported rates of local recurrence after RF ablation for HCC 
of 19% to 36% (30-35), which is in accordance with the 
results of our study. Also, numerous studies demonstrated 
the 5-year post-RF ablation overall survival rates ranged 
from 33% to 58%, supporting that RF ablation may be 
accepted as primary treatment for patients with HCC for 
whom hepatectomy or liver transplantation was not suitable 
(5, 8, 17, 31-33, 36).
We were concerned about possible influences of 
prognostic factors on local recurrence-free rates and survival 
rates. However, we found only HCC size was a significant 
prognostic factor in local recurrence-free rates. Local 
recurrence-free rate was higher in patients with small HCC (≤ 
2 cm). Generally, RF ablation treatment is known to induce 
a spherical thermal lesion measuring approximately 3 cm at 
its greatest dimension in a single session (37). Accordingly, 
ablation of HCCs larger than 3 cm may require repeated 
sessions. Komorizono et al. reported that an HCC dimension 
> 2 cm was associated independently with local recurrence 
after a single session RF ablation, which is in accordance 
with the results of our study (38).
Complications after RF ablation for HCC have been 
reported. The rate of complications for the treatment of 
HCC was reported to be greater than 5% (12, 14, 17, 26). 
The relatively high rate of complications may be due to 
the prevalence of liver cirrhosis in patients treated. The 
complications we observed in our investigation were similar 
to those of studies dealing with HCC associated with liver 
cirrhosis. 
Our study has several limitations. First, this study was 
retrospectively performed and was not randomized in 
design. Second, most HCCs were not pathological confirmed. 
Third, this study included a relatively small number of 
patients.
In conclusion, ultrasound-guided RF ablation could be an 
effective and safe method for treating incompletely treated 
HCC after TACE. The diameter of HCC was a significant 
prognostic factor for local recurrence.
Fig. 4. Graph illustrates overall survival rate. 1-, 2-, 3-, and 
5-year overall survival rates were 96.9%, 82.9%, 67.8%, and 48.4%, 
respectively. 
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Table 1. Prognostic Factors That Could Affect Local 
Recurrence Free Rate
Characteristics
Numbers 
of Patients 
(n = 39)
P Value
HCC size > 2 cm 22 0.047
≤ 2 cm 17
Number of previous 
  TACE
≥ 2 17 0.529
1 22
Patient age > 66 19 0.062
≤ 66 20
Patient gender  Male 33 0.262
Female 6
Alcoholic liver disease + 14 0.710
- 25
Hepatitis B + 25 0.173
- 14
Hepatitis C + 11 0.453
- 28
Child-Pugh class A 19 0.274
B 20
Alpha-fetoprotein 
  (ng/mL)
> 100 5 0.202
≤ 100 34
Interval between 
  TACE and RF ablation
> 2 months 19 0.455
≤ 2 months 20
Note.— TACE = transcatheter arterial chemoembolization, RF = 
radiofrequency
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